PubMed · 15328133
Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin.
Abstract
The susceptibility of 135 vancomycin-resistant Enterococcus faecium bacteremic isolates to linezolid and quinupristin-dalfopristin was determined. All were susceptible to linezolid, while 88% were susceptible to quinupristin-dalfopristin prior to the clinical use of the drugs at our hospital. More than 6 months after their clinical use, a decrease in susceptibility was noted for only linezolid at 83%. This was related in part to a single G2576U gene mutation in domain V of the 23S rRNA gene.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Issam I Raad, Hend A Hanna, Ray Y Hachem, Tanya Dvorak, Rebecca B Arbuckle, Gassan Chaiban, Louis B Rice. 2004. Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin.. https://doi.org/10.1128/aac.48.9.3583-3585.2004
Cite the original work for its findings. Save a collection to share your selection of sources.